Back to results
US 2023/0054546 A1Published application
Use of oligosaccharide riclinoctaose in preparation of drug for treating and/or preventing ischemia-reperfusion injury (iri)
AssigneeNanjing Southern Element Biotechnology Co., Ltd.
InventorsJianfa ZHANG, Ni WANG, Yang ZHAO
Life of this patent
Estimating the term…
Abstract
Oligosaccharide riclinoctaose is used in preparation of a drug for treating and/or preventing ischemia-reperfusion injury (IRI). The oligosaccharide riclinoctaose has a structural formula as follows: The oligosaccharide riclinoctaose can significantly relieve postoperative liver injury, kidney injury, and brain injury in ischemia-reperfusion mice.
Claims8
A method for treating ischemia-reperfusion injury (IRI) by oligosaccharide riclinoctaose, wherein the oligosaccharide riclinoctaose has a structural formula as follows:
Dependencies are inferred from the claim text.